Bupleurum-based formulas and their modern preparations: from ancient usage to clinical application
Year: 2026
Type: article
Study design: Systematic Review
Abstract: Ethnopharmacological relevance Bupleuri Radix (Bupleurum) has been used in Chinese, Japanese, and Korean herbal medicine for over two millennia. It was first recorded in Shennong Bencao Jing and was extensively used in Zhang Zhongjing’s Shanghan Lun. Traditionally, it is used for “harmonizing Shaoyang” and “soothing the liver and relieving depression.” Modern pharmacological studies support these traditional applications and have revealed anti-inflammatory, hepatoprotective, and antidepressant activities, thereby bridging traditional efficacy and modern science. Aim of the review This review systematically summarizes the historical evolution, pharmacological mechanisms, and contemporary development of Bupleurum and its compound formulas. It traces their transition from traditional decoctions to modern dosage forms, discusses current challenges, and proposes a strategic framework to promote clinical application and the modernization of TCM. Materials and methods We systematically searched PubMed, Web of Science, and CNKI from database inception to July 2026. The search was supplemented with official monographs, including the Chinese Pharmacopoeia (2025 edition). Studies on botany, phytochemistry, pharmacology, quality control, and clinical application were screened using predefined criteria. Eligible studies included peer-reviewed original research on Bupleurum species. Data extraction and synthesis followed PRISMA guidelines. Duplicate publications, conference abstracts, and studies unrelated to Bupleurum were excluded. Results This review identified 109 modern Bupleurum-containing preparations in the Chinese Pharmacopoeia (2025 edition). The major constituents—saikosaponins, polysaccharides, flavonoids, and volatile oils—exert diverse biological activities. These include anti-inflammatory effects via NF-κB/MAPK modulation, antitumor effects via PI3K/Akt/mTOR and STAT3 regulation, antidepressant effects via monoamine modulation, BDNF/TrkB signaling, and gut microbiota remodeling, and hepatoprotective effects via Nrf2/ARE and PPAR-α activation. Three classical formulas—Xiao Chaihu Tang, Buzhong Yiqi Tang, and Xiaoyao San—have been developed into modern dosage forms. This review integrates the legacy of Bupleurum into a “herb–component–target–disease” framework and identifies limitations in quality consistency, bioavailability, mechanistic elucidation, and clinical translation. Conclusion This review provides a comprehensive foundation for modernizing Bupleurum-containing formulas by integrating historical applications with contemporary pharmacology and pharmaceutical science. Future studies should adopt the “herb–component–target–disease” paradigm using network pharmacology, multi-omics, and high-throughput screening. Drug delivery systems, such as nanoformulations and sustained-release preparations, should be further developed. Comprehensive quality control should combine chemical fingerprinting with bioactivity assessments. Well-designed, large-scale randomized controlled trials are also needed to strengthen the evidence base and promote the international recognition.
Source: Frontiers in Pharmacology
Language: English
Subfield: Complementary and alternative medicine
Field: Medicine
Domain: Health Sciences
Keywords: Bupleurum, Xiaoyaosan, saikosaponins, modernization of traditional Chinese medicine, herbal decoction, anti-inflammatory activity, hepatoprotection, antidepressant effects, gut microbiota, Nrf2/ARE pathway, PPARα, MAPK/NF-κB signaling, herbal medicine quality control, bioavailability, clinical translation
Open Access status: gold
Estimated APC paid: $3,801
Awards: G352136246, G7430438285
OpenAlex ID: W7236755148
